PROCEPT BioRobotics/$PRCT

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About PROCEPT BioRobotics

PROCEPT BioRobotics Corp is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. It develops, manufactures, and sells the AquaBeam Robotic System and HYDROS Robotic System, which are image-guided, surgical robotic systems for use in minimally invasive urologic surgery, with an initial focus on treating benign prostatic hyperplasia, or BPH. Geographically, the company generates a majority of its revenue from the United States and also has a presence in markets outside the U.S.

Ticker

$PRCT
Sector
Primary listing

Employees

756

PRCT Metrics

BasicAdvanced
$1.9B
-
-$1.56
1.04
-

What the Analysts think about PRCT

Analyst ratings (Buy, Hold, Sell) for PROCEPT BioRobotics stock.

Bulls say / Bears say

PROCEPT reported Q2 2025 revenue of $79.2 million, marking a 48% year-over-year increase and surpassing prior guidance by $2.5 million, underscoring strong procedural adoption. (Nasdaq)
Q2 gross margin expanded to 65%, up from 59% a year ago, driven by improved operational efficiencies and higher average selling prices, indicating scalable unit economics. (Nasdaq)
The appointment of medtech veteran Larry L. Wood as CEO effective September 2, 2025, brings over 40 years of leadership experience from Edwards Lifesciences, potentially enhancing strategic execution. (Investing.com)
The company recorded an adjusted EBITDA loss of $8.0 million in Q2 and forecasts a full-year EBITDA loss of $35.0 million, highlighting persistent profitability challenges. (Nasdaq)
Operating expenses climbed to $73.9 million in Q2, a 27% increase year-over-year driven by commercial and R&D investments, which may strain cash flow if revenue growth decelerates. (Nasdaq)
International revenue of $9.6 million in Q2 comprised just 12% of total sales, underscoring significant dependence on the U.S. market and limited global diversification. (Seeking Alpha)
Data summarised monthly by Lightyear AI. Last updated on 3 Oct 2025.

PRCT Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

PRCT Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $PRCT

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs
Buy PROCEPT BioRobotics stock | $PRCT Share Price | Lightyear